Guillain–Barré Syndrome Associated with COVID-19 in a Japanese Male

Figure 1

Clinical course of the disease. The diagram shows the clinical severity of dysphagia and weakness of the limbs from the onset of Guillain–Barré syndrome on day 1. The arrows indicate Guillain–Barré syndrome treatment with intravenous immunoglobulin (white) and intravenous methylprednisolone (black). On day 7, he showed severe muscle weakness in his neck and extremities, dysphagia, and respiratory difficulties. Thereafter, each symptom improved, and he was discharged on day 40 with minimal muscle fatigue. Abbreviations: IVIg, intravenous immunoglobulin; IVMP, intravenous methylprednisolone; SARS-CoV-2 RNA, severe acute respiratory syndrome coronavirus 2 ribonucleic acid.